In the colon, LOSWIFT™Lactulose is degraded into short-chain fatty acids (SCFA) during bacterial fermentation. Thus, the intestinal content acidifies, the osmotic pressure rises and stool volume increases, which causes the pH to decrease. This decrease in pH increases the formation of ammonium ions, which unlike ammonia, cannot diffuse through the intestinal mucosa. This leads to characterizing the laxative effect of LOSWIFT™Lactulose by shorter colon transit time and accelerated bowel movement. All these factors are favourable for a healthy bowel.

Compared with traditional stimulant laxatives, LOSWIFT™Lactulose has a milder effect, does not cause intestinal spasms and electrolyte disorders, and is safe for long-term use, especially suitable for patients with chronic constipation and the elderly.

Colon cancer develops from the lining of the large intestine or colon. In 70% of cases, the tumour grows in the sigmoid (loop located in the left iliac fossa). In the context of colon carcinoma, the lowered faecal concentrations of secondary bile salts are noticed when LOSWIFT™Lactulose was administered to healthy volunteers.

It was reported that the recurrence rate of colon adenomas in the large bowel was reduced after LOSWIFT™Lactulose administration. Moreover, LOSWIFT™Lactulose suppressed DNA damage in the colon mucosa of rats treated with 1,2-dimethylhydrazine. These findings suggest that LOSWIFT™Lactulose may have potential protective effects against colon carcinogenesis.

LOSWIFT™Lactulose can significantly augment the absorption of calcium, if the alimentation contains at least 0.3% of calcium. Magnesium is poorly absorbed: intestinal absorption is about 30%. By performing tests on rats, it has been shown that LOSWIFT™Lactulose promotes the absorption and retention in the body of several minerals such as Ca, Mg, Zn, Cu, Fe.

The effect of LOSWIFT™Lactulose on the rat's bone strength was studied. The results showed that LOSWIFT™Lactulose increases the absorption of calcium in both osteoporosis and bone strength. It has been reported that LOSWIFT™Lactulose increases the absorptions of Ca and Mg in dogs and rats, and increases the rupture strength of the femur in an ovariectomized rat model of osteoporosis.

A study performed on adult men showed that the absorption of calcium and magnesium increases with increasing amounts of LOSWIFT™Lactulose administration. Significant differences were observed in the calcium ratio between 0 and 4 g of LOSWIFT™Lactulose; and in the magnesium ratios between 0 and 2 g of LOSWIFT™Lactulose and between 0 and 4 g of LOSWIFT™Lactulose. This clinical trial has confirmed that LOSWIFT™Lactulose enhances the absorptions of Ca and Mg.

LOSWIFT™Lactulose reduces bacterial production of ammonia in the intestines, draws ammonia from the blood to the colon and then drains it through the waste. LOSWIFT™Lactulose is hydrolysed by colonic bacteria and acts as promoting agent for their growth and increasing biomass formation.

For the synthesis of bacterial protein, ammonia and nitrogen are used, but the production of ammonia is inhibited by acidifying the intestinal content. Independent of pH, LOSWIFT™Lactulose acts by increasing the incorporation of ammonia in the bacterial proteins.

In addition, it has been shown in vitro that LOSWIFT™Lactulose inhibits the synthesis and the activity of bacterial enzymes that generate ammonia. This mechanism makes LOSWIFT™Lactulose particularly valuable in treating hepatic encephalopathy and conditions involving elevated blood ammonia levels.